MED18

Across TCGA pan-cancer cohorts, MED18 RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated MED18 data layer compared with 1 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher MED18 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated MED18 expression acts as an unfavorable survival marker, although some lineages such as COAD and STAD show a favorable association.

COAD, LIHC, and STAD are the cancer types where MED18 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Tertile	All	0.840	0.708	.001	70	view →
LIHC	DFS	Quartile	All	0.305	0.520	<.001	58	view →
STAD	OS	Quartile	All	0.820	0.562	<.001	55	view →
KIRC	DFS	Median	All	0.787	0.460	<.001	54	view →
LGG	DFS	Median	All	0.650	0.821	<.001	53	view →
LAML	DFS	Median	All	0.477	0.651	.009	26	view →
THYM	OS	Median	All	1.000	0.920	.010	22	view →
SCLC	DFS	Quartile	II,III,IV	0.624	0.218	.003	21	view →
KICH	DFS	Median	II,III,IV	0.705	0.959	.011	19	view →
ACC	DFS	Quartile	All	0.248	0.754	.010	18	view →
CHOL	DFS	Tertile	III,IV	0.779	0.164	.024	12	view →
OV	DFS	Tertile	II,III,IV	0.129	0.218	.036	8	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

MED18–COAD (DFS)

Open the COAD breakdown →